Business
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
AI Simulation on MIRA1a Showcases Significant Potential Advantages Over Plant-Based Medical Marijuana Related to Anxiety, Appetite and Cognition BALTIMORE,
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"AI Simulation on MIRA1a Showcases Significant Potential Advantages Over Plant-Based Medical Marijuana Related to Anxiety, Appetite and Cognition \nBALTIMORE, Dec. 4, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (\"MIRA\" or the \"Company\"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic and neuropsychiatric disorders, has released new data from artificial intelligence (AI) simulations that show that, compared to plant-based medical marijuana, there may be significant potential advantages to the therapeutic potential of MIRA1a, such as its potential to offer a superior anti-anxiety treatment, increased cognition and without the increased appetite associated with THC.\n\nThe simulations on MIRA1a were conducted in conjunction with the Company's strategic collaboration with InSilicoTrials, a company specializing in leveraging AI and simulations to enhance drug and medical device development.\nIn silico analysis is a computational technique that uses AI to predict the interaction between drugs and their targets. This innovative approach facilitates the virtual screening of compounds and the assessment of their pharmacological profiles before physical trials, expediting drug development and increasing the precision of therapeutic targeting.\n\"The results of our AI analysis work with InSilicoTrial's efforts continue to validate MIRA1a as a potential pharmaceutical candidate within a multi-billion-dollar market to address the unmet needs of millions with anxiety and cognition issues with potentially fewer negative side effects than THC,\" said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals. \"Following positive results from recent in vivo animal testing and research indicating MIRA1a's potential therapeutic effects, without the common negative side effects seen with THC even at high doses, we believe these targeted studies with InSilicoTrials employing artificial intelligence and machine learning further underscores MIRA1a's position as a promising development in the evolution of neuropharmacological therapies as we work towards the goal of filing an Investigational New Drug (\"IND\") Application with the Food and Drug Administration (\"FDA\").\"\nDecoding MIRA1a's Potential: A Possible Breakthrough in Anxiety, Appetite, and Cognition\nThrough meticulous computer-aided si...